GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer

Lorraine Pelosof, Sashidhar Yerram, Todd Armstrong, Nina Chu, Ludmila Danilova, Breann Yanagisawa, Manuel Hidalgo, Nilofer Azad, James G. Herman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Epigenetic control of gene expression is a major determinant of tumor phenotype and has been found to influence sensitivity to individual chemotherapeutic agents. Glutathione peroxidase 3 (GPX3, plasma glutathione peroxidase) is a key component of cellular antioxidant regulation and its gene has been reported to be methylated in specific tumor types. GPX3 role in oxidative damage has been associated with sensitivity to platinums in other tumors but its importance in colorectal cancer (CRC) has not been determined. We examined the role of GPX3 methylation in colorectal carcinoma in determining sensitivity to platinum drugs using primary tumor specimens, cell lines, knockdown cell lines, and tumor cell line xenografts. We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity. In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased. The cisplatin IC50 in GPX3-methylated cell lines is approximately 6-fold lower than that in GPX3-unmethylated lines. Additionally, knockdown cell lines with essentially no GPX3 expression require N-acetylcysteine to survive in culture underscoring the importance of GPX3 in redox biology. In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum. These studies demonstrate the importance of GPX3 for CRC cells resistance to platinums and the potential utility of GPX3 methylation status as a predictive biomarker for platinum sensitivity in CRC.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalEpigenetics
DOIs
StateAccepted/In press - Jul 3 2017

Fingerprint

Platinum
Methylation
Colorectal Neoplasms
Heterografts
Cell Line
oxaliplatin
Glutathione Peroxidase
Tumor Cell Line
Cisplatin
Neoplasms
Acetylcysteine
Genetic Promoter Regions
Epigenomics
Inhibitory Concentration 50
Oxidation-Reduction
Antioxidants
Biomarkers
Phenotype
Gene Expression
Growth

Keywords

  • Cisplatin
  • colorectal cancer
  • GPX3
  • methylation
  • oxaliplatin

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Pelosof, L., Yerram, S., Armstrong, T., Chu, N., Danilova, L., Yanagisawa, B., ... Herman, J. G. (Accepted/In press). GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics, 1-11. https://doi.org/10.1080/15592294.2016.1265711

GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. / Pelosof, Lorraine; Yerram, Sashidhar; Armstrong, Todd; Chu, Nina; Danilova, Ludmila; Yanagisawa, Breann; Hidalgo, Manuel; Azad, Nilofer; Herman, James G.

In: Epigenetics, 03.07.2017, p. 1-11.

Research output: Contribution to journalArticle

Pelosof, L, Yerram, S, Armstrong, T, Chu, N, Danilova, L, Yanagisawa, B, Hidalgo, M, Azad, N & Herman, JG 2017, 'GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer', Epigenetics, pp. 1-11. https://doi.org/10.1080/15592294.2016.1265711
Pelosof L, Yerram S, Armstrong T, Chu N, Danilova L, Yanagisawa B et al. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. Epigenetics. 2017 Jul 3;1-11. https://doi.org/10.1080/15592294.2016.1265711
Pelosof, Lorraine ; Yerram, Sashidhar ; Armstrong, Todd ; Chu, Nina ; Danilova, Ludmila ; Yanagisawa, Breann ; Hidalgo, Manuel ; Azad, Nilofer ; Herman, James G. / GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer. In: Epigenetics. 2017 ; pp. 1-11.
@article{c1b228f3a7e6480d9a884c4a4eadb8a3,
title = "GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer",
abstract = "Epigenetic control of gene expression is a major determinant of tumor phenotype and has been found to influence sensitivity to individual chemotherapeutic agents. Glutathione peroxidase 3 (GPX3, plasma glutathione peroxidase) is a key component of cellular antioxidant regulation and its gene has been reported to be methylated in specific tumor types. GPX3 role in oxidative damage has been associated with sensitivity to platinums in other tumors but its importance in colorectal cancer (CRC) has not been determined. We examined the role of GPX3 methylation in colorectal carcinoma in determining sensitivity to platinum drugs using primary tumor specimens, cell lines, knockdown cell lines, and tumor cell line xenografts. We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity. In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased. The cisplatin IC50 in GPX3-methylated cell lines is approximately 6-fold lower than that in GPX3-unmethylated lines. Additionally, knockdown cell lines with essentially no GPX3 expression require N-acetylcysteine to survive in culture underscoring the importance of GPX3 in redox biology. In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum. These studies demonstrate the importance of GPX3 for CRC cells resistance to platinums and the potential utility of GPX3 methylation status as a predictive biomarker for platinum sensitivity in CRC.",
keywords = "Cisplatin, colorectal cancer, GPX3, methylation, oxaliplatin",
author = "Lorraine Pelosof and Sashidhar Yerram and Todd Armstrong and Nina Chu and Ludmila Danilova and Breann Yanagisawa and Manuel Hidalgo and Nilofer Azad and Herman, {James G.}",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/15592294.2016.1265711",
language = "English (US)",
pages = "1--11",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer

AU - Pelosof, Lorraine

AU - Yerram, Sashidhar

AU - Armstrong, Todd

AU - Chu, Nina

AU - Danilova, Ludmila

AU - Yanagisawa, Breann

AU - Hidalgo, Manuel

AU - Azad, Nilofer

AU - Herman, James G.

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Epigenetic control of gene expression is a major determinant of tumor phenotype and has been found to influence sensitivity to individual chemotherapeutic agents. Glutathione peroxidase 3 (GPX3, plasma glutathione peroxidase) is a key component of cellular antioxidant regulation and its gene has been reported to be methylated in specific tumor types. GPX3 role in oxidative damage has been associated with sensitivity to platinums in other tumors but its importance in colorectal cancer (CRC) has not been determined. We examined the role of GPX3 methylation in colorectal carcinoma in determining sensitivity to platinum drugs using primary tumor specimens, cell lines, knockdown cell lines, and tumor cell line xenografts. We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity. In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased. The cisplatin IC50 in GPX3-methylated cell lines is approximately 6-fold lower than that in GPX3-unmethylated lines. Additionally, knockdown cell lines with essentially no GPX3 expression require N-acetylcysteine to survive in culture underscoring the importance of GPX3 in redox biology. In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum. These studies demonstrate the importance of GPX3 for CRC cells resistance to platinums and the potential utility of GPX3 methylation status as a predictive biomarker for platinum sensitivity in CRC.

AB - Epigenetic control of gene expression is a major determinant of tumor phenotype and has been found to influence sensitivity to individual chemotherapeutic agents. Glutathione peroxidase 3 (GPX3, plasma glutathione peroxidase) is a key component of cellular antioxidant regulation and its gene has been reported to be methylated in specific tumor types. GPX3 role in oxidative damage has been associated with sensitivity to platinums in other tumors but its importance in colorectal cancer (CRC) has not been determined. We examined the role of GPX3 methylation in colorectal carcinoma in determining sensitivity to platinum drugs using primary tumor specimens, cell lines, knockdown cell lines, and tumor cell line xenografts. We find GPX3 promoter region methylation in approximately one third of CRC samples and GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity. In contrast, in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased. The cisplatin IC50 in GPX3-methylated cell lines is approximately 6-fold lower than that in GPX3-unmethylated lines. Additionally, knockdown cell lines with essentially no GPX3 expression require N-acetylcysteine to survive in culture underscoring the importance of GPX3 in redox biology. In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum. These studies demonstrate the importance of GPX3 for CRC cells resistance to platinums and the potential utility of GPX3 methylation status as a predictive biomarker for platinum sensitivity in CRC.

KW - Cisplatin

KW - colorectal cancer

KW - GPX3

KW - methylation

KW - oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=85025125133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025125133&partnerID=8YFLogxK

U2 - 10.1080/15592294.2016.1265711

DO - 10.1080/15592294.2016.1265711

M3 - Article

SP - 1

EP - 11

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

ER -